HUTCHMED China Ltd (HCM) - Net Assets

Latest as of June 2025: GBX1.24 Billion GBX

Based on the latest financial reports, HUTCHMED China Ltd (HCM) has net assets worth GBX1.24 Billion GBX as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.78 Billion) and total liabilities (GBX534.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX1.24 Billion
% of Total Assets 69.93%
Annual Growth Rate N/A
5-Year Change 48.73%
10-Year Change 654.67%
Growth Volatility 47.69

HUTCHMED China Ltd - Net Assets Trend (2005–2024)

This chart illustrates how HUTCHMED China Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for HUTCHMED China Ltd (2005–2024)

The table below shows the annual net assets of HUTCHMED China Ltd from 2005 to 2024.

Year Net Assets Change
2024-12-31 GBX771.85 Million +3.83%
2023-12-31 GBX743.39 Million +16.73%
2022-12-31 GBX636.87 Million -38.73%
2021-12-31 GBX1.04 Billion +100.31%
2020-12-31 GBX518.95 Million +65.85%
2019-12-31 GBX312.90 Million -24.10%
2018-12-31 GBX412.25 Million -14.99%
2017-12-31 GBX484.97 Million +137.66%
2016-12-31 GBX204.06 Million +99.52%
2015-12-31 GBX102.28 Million -14.69%
2014-12-31 GBX119.88 Million +14.35%
2013-12-31 GBX104.84 Million +25.33%
2012-12-31 GBX83.65 Million +8.17%
2011-12-31 GBX77.33 Million +12.39%
2010-12-31 GBX68.81 Million -8.62%
2009-12-31 GBX75.30 Million -10.81%
2008-12-31 GBX84.43 Million -13.50%
2007-12-31 GBX97.61 Million -11.25%
2006-12-31 GBX109.98 Million +492.65%
2005-12-31 GBX-28.01 Million --

Equity Component Analysis

This analysis shows how different components contribute to HUTCHMED China Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 79902748560.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock GBX87.16 Million 11.47%
Other Comprehensive Income GBX-11.59 Million -1.52%
Other Components GBX1.52 Billion 199.69%
Total Equity GBX759.93 Million 100.00%

HUTCHMED China Ltd Competitors by Market Cap

The table below lists competitors of HUTCHMED China Ltd ranked by their market capitalization.

Company Market Cap
ECM Libra Financial Group Bhd
KLSE:2143
 		$23.01 Million
Ttbio Corp.
TWO:6493
 		$23.01 Million
Alumexx N.V.
AS:ALX
 		$23.01 Million
Four Seasons Education Cayman
NYSE:FEDU
 		$23.02 Million
Global Uranium and Enrichment Ltd
AU:GUE
 		$22.99 Million
PJX Resources Inc
V:PJX
 		$22.99 Million
CVD Equipment Corporation
NASDAQ:CVV
 		$22.99 Million
431190
KQ:431190
 		$22.98 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HUTCHMED China Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 730,541,000 to 759,929,000, a change of 29,388,000 (4.0%).
  • Net income of 37,729,000 contributed positively to equity growth.
  • Share repurchases of 36,064,000 reduced equity.
  • New share issuances of 790,000 increased equity.
  • Other comprehensive income decreased equity by 3,422,000.
  • Other factors increased equity by 30,355,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX37.73 Million +4.96%
Share Repurchases GBX36.06 Million -4.75%
Share Issuances GBX790.00K +0.1%
Other Comprehensive Income GBX-3.42 Million -0.45%
Other Changes GBX30.36 Million +3.99%
Total Change GBX- 4.02%

Book Value vs Market Value Analysis

This analysis compares HUTCHMED China Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 252.60x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 GBX-0.09 GBX220.00 x
2006-12-31 GBX0.23 GBX220.00 x
2007-12-31 GBX0.18 GBX220.00 x
2008-12-31 GBX0.15 GBX220.00 x
2009-12-31 GBX0.13 GBX220.00 x
2010-12-31 GBX0.12 GBX220.00 x
2011-12-31 GBX0.12 GBX220.00 x
2012-12-31 GBX0.13 GBX220.00 x
2013-12-31 GBX0.17 GBX220.00 x
2014-12-31 GBX0.18 GBX220.00 x
2015-12-31 GBX0.15 GBX220.00 x
2016-12-31 GBX0.31 GBX220.00 x
2017-12-31 GBX0.75 GBX220.00 x
2018-12-31 GBX0.59 GBX220.00 x
2019-12-31 GBX0.43 GBX220.00 x
2020-12-31 GBX0.69 GBX220.00 x
2021-12-31 GBX1.25 GBX220.00 x
2022-12-31 GBX0.77 GBX220.00 x
2023-12-31 GBX0.84 GBX220.00 x
2024-12-31 GBX0.87 GBX220.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HUTCHMED China Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.96%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.99%
  • • Asset Turnover: 0.49x
  • • Equity Multiplier: 1.68x
  • Recent ROE (4.96%) is above the historical average (-9.47%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 0.00% -17.90% 0.60x 0.00x GBX-3.41 Million
2006 -9.33% -19.05% 0.38x 1.29x GBX-19.90 Million
2007 -19.04% -26.40% 0.51x 1.41x GBX-26.22 Million
2008 -23.63% -20.41% 0.74x 1.57x GBX-25.27 Million
2009 -13.28% -7.88% 0.87x 1.94x GBX-15.34 Million
2010 -11.53% -5.10% 0.84x 2.69x GBX-12.82 Million
2011 1.10% 0.43% 0.86x 3.01x GBX-5.77 Million
2012 5.15% 1.86% 0.93x 2.97x GBX-3.42 Million
2013 6.66% 12.87% 0.25x 2.09x GBX-2.97 Million
2014 5.66% 5.85% 0.42x 2.31x GBX-4.11 Million
2015 9.59% 4.49% 0.78x 2.76x GBX-342.60K
2016 6.35% 5.41% 0.63x 1.86x GBX-6.73 Million
2017 -5.79% -11.08% 0.40x 1.29x GBX-72.91 Million
2018 -19.23% -34.94% 0.40x 1.37x GBX-113.70 Million
2019 -36.00% -50.60% 0.44x 1.61x GBX-132.48 Million
2020 -25.97% -55.15% 0.31x 1.50x GBX-174.14 Million
2021 -19.72% -54.66% 0.26x 1.39x GBX-293.34 Million
2022 -59.12% -84.62% 0.41x 1.69x GBX-421.87 Million
2023 13.80% 12.03% 0.65x 1.75x GBX27.73 Million
2024 4.96% 5.99% 0.49x 1.68x GBX-38.26 Million

Industry Comparison

This section compares HUTCHMED China Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,174,646,097
  • Average return on equity (ROE) among peers: -156.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HUTCHMED China Ltd (HCM) GBX1.24 Billion 0.00% 0.43x $23.00 Million
MERCK Kommanditgesellschaft auf Aktien (0O14) $26.75 Billion 10.56% 0.81x $17.92 Billion
Allergy Therapeutics (AGY) $37.77 Million -36.48% 0.93x $7.85 Million
Animalcare Group Plc (ANCR) $15.38 Million 6.75% 0.65x $2.80 Million
Alliance Pharma plc (APH) $7.50 Million 8.81% 3.77x $4.26 Million
Beximco Pharmaceuticals Limited (BXP) $8.25 Billion 4.28% 0.45x $2.31 Million
Celadon Pharmaceuticals PLC (CEL) $99.03K -1412.59% 37.89x $112.25K
Chill Brands Group PLC (CHLL) $-1.23 Million 0.00% 0.00x $33.40K
Eco Animal Health Group Plc (EAH) $95.31 Million 7.70% 0.23x $812.15K
Hikma Pharmaceuticals PLC (HIK) $2.41 Billion 6.43% 0.81x $37.16 Million

About HUTCHMED China Ltd

LSE:HCM UK Drug Manufacturers - Specialty & Generic
Market Cap
$23.00 Million
GBX189.05 Billion GBX
Market Cap Rank
#27531 Global
#477 in UK
Share Price
GBX220.00
Change (1 day)
+0.00%
52-Week Range
GBX193.00 - GBX286.00
All Time High
GBX624.00
Categories
Companies in UK Drug Manufacturers - Specialty & Generic
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more